CHARITÉ - UNIVERSITAETSMEDIZIN BERLIN (CHARITE)

Berlin, Germany

Charité – Universitätsmedizin Berlin is one of the largest university hospitals in Europe, delivering outstanding clinical care, research, and teaching. Charité proudly lays claim to the majority of all German Nobel Prize winners in Physiology and Medicine, including Emil von Behring, Robert Koch, and Paul Ehrlich.

The Yellow4FLAVI team at Charité has profound expertise in medical risk communication, with a special interest in communication around the risks and effectiveness of vaccines.

Project Team

Prof. Dr. Odette Wegwarth

Odette Wegwarth holds the Heisenberg Chair for Medical Risk Literacy and Evidence-Based Decisions at Charité Berlin. She is a nationally and internationally recognized expert in designing and communicating risk and uncertainty transparently and has received prizes for her innovative research in the field of risk communication.

Dr. Helge Andreas Giese

Helge Giese is a senior research scientist in the Heisenberg Professorship for Medical Risk Literacy and Evidence-Based Decisions. He is a psychologist with a specific focus on the social dynamics of health decision making. In this line, he also strives to optimize risk and effectiveness communication of vaccines for digital environments.

Paula Dau

Paula Dau is a research scientist in the Heisenberg Professorship for Medical Risk Literacy and Evidence-Based Decisions. She holds a M.Sc. in Health Science with a focus on Prevention and Health Promotion from Technical University of Munich. Her main research interests include global health, implementation research and factors for acceptance and uptake of preventive measures.

Miriam Rumpel

Scientific coordinator Miriam Rumpel holds an M.A. in Philosophy from the University of Cambridge and an M.Sc. in Cognitive Science from the University of Potsdam.

Project tasks

Work Package 5 Mixed-methods research on perceptions of novel vaccine technologies

and conceptions of (vaccine induced) immunity: lessons for (flavivirus) risk communication

Work Package 5 Lead: Mixed-methods research on perceptions of novel vaccine technologies and conceptions of (vaccine induced) immunity: lessons for (flavivirus) risk communication

Task 5.1. Conceptions of (vaccine-induced) immunity and novel vaccine technologies – a qualitative study
Task 5.2. Lead: Prevalence of knowledge and acceptance of novel vaccine technologies and perceived barriers to vaccination, preparedness uptake and in cross-cultural comparison
Task 5.3. Lead: Theory-based experimental communication intervention to increase vaccination education and acceptance, in particular in vulnerable subpopulations

Task 5.4. Lead: Public roll-out of vaccine risk communication materials and strategies